Invention Grant
- Patent Title: Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
-
Application No.: US16562236Application Date: 2019-09-05
-
Publication No.: US11291720B2Publication Date: 2022-04-05
- Inventor: Baiyong Li , Yu Xia , Zhongmin Wang , Peng Zhang , Xinghua Pang
- Applicant: AKESO BIOPHARMA, INC.
- Applicant Address: CN Guangdong
- Assignee: AKESO BIOPHARMA, INC.
- Current Assignee: AKESO BIOPHARMA, INC.
- Current Assignee Address: CN Guangdong
- Agency: Faegre Drinker Biddle & Reath LLP
- Priority: CN201410377352.9 20140801
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C12N15/63 ; C12N5/10 ; C07K19/00 ; C07K16/28 ; G01N33/577 ; A61K49/00
Abstract:
The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
Public/Granted literature
- US20200206346A1 ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USES Public/Granted day:2020-07-02
Information query
